Gemcitabine plus celecoxib after pancreatic surgery
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests whether adding celecoxib to gemcitabine chemotherapy after complete (R0) pancreatic tumor removal can lower the chance the cancer comes back. It may help people who have had successful surgery but still need anti-cancer treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- Your pancreatic surgery removed all cancer with clear margins (R0 resection).
- You have not previously used a gemcitabine chemotherapy regimen for other cancers.
- Your general strength is good (performance status score 0 to 2).
- Your blood counts and organ tests are in safe ranges (enough white cells, platelets, and hemoglobin; liver and kidney function not too high/low).
- You can take celecoxib (no true allergy, and you can take it without needing ongoing aspirin or similar anti-inflammatory pain medicines).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether adding canagliflozin to standard chemotherapy (gemcitabine) can slow pancreatic cancer that cannot be fully removed by surgery. It may help some people control the cancer for longer and improve how well treatment works.
This trial tests a new chemotherapy combination (HR070803 plus two other drugs) given after surgery to see if it prevents pancreatic cancer from coming back better than the current standard treatment.
This trial tests if giving a combination of four drugs before and after surgery can help treat pancreatic cancer. The drugs include HRS-4642, gemcitabine, nab-paclitaxel, and adebrelimab. It may help shrink the tumor before surgery and lower the chance of cancer coming back afterward.
This trial tests adding the immunotherapy drug adebrelimab to standard chemotherapy before surgery for pancreatic cancer that can be removed. The goal is to see if this combination shrinks tumors more effectively.
This trial tests whether adding a traditional Chinese herb (Astragalus) to a standard chemotherapy drug (gemcitabine) before surgery works better than gemcitabine alone for treating pancreatic cancer. People who can join will have locally advanced or borderline resectable cancer that hasn't spread to distant organs.
This study tests whether adding pitavastatin (a cholesterol-lowering drug) to gemcitabine chemotherapy can help treat pancreatic cancer that cannot be surgically removed. You would join if your cancer hasn't grown worse after 2–4 rounds of gemcitabine.
Hear when a new Pancreatic cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.